FDA Measures Naloxone Price Trend In Considering Wider Availability
This article was originally published in The Tan Sheet
Even though FDA cannot consider drug pricing, it gives research of naloxone sales to inform workshop on uptake and use. Amphastar’s naloxone prices are being scrutinized by state officials and a House member.
You may also be interested in...
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.
One-Page Patient Medication Information Document Moves Forward Under Proposed Rule
After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.
Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?
New ICH draft guidance says a fed study is not necessary for most immediate-release solid oral dosage products and the FDA indicates it will consider revising product-specific guidances to harmonize standards.